Anzeige
Mehr »
Login
Donnerstag, 25.02.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Breaking News & Strong Buy: Kupferrakete Bam Bam Resources meldet Neuentdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 881535 ISIN: US75886F1075 Ticker-Symbol: RGO 
Tradegate
24.02.21
21:48 Uhr
378,00 Euro
-7,30
-1,89 %
1-Jahres-Chart
REGENERON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
REGENERON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
375,50377,4024.02.
375,65378,6024.02.

Aktuelle News zur REGENERON PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBiotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates6
REGENERON PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiSanofi, Regeneron's Libtayo scores first-line NSCLC approval in the US7
DiSanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-1112
DiSanofi, Regeneron's Libtayo snags lung cancer nod, taking a stab at Keytruda's megablockbuster lead9
MoRegeneron, Sanofi erhalten erweiterte US-Zulassung für Libtayo413DJ Regeneron, Sanofi erhalten erweiterte US-Zulassung für Libtayo Von Colin Kellaher NEW YORK (Dow Jones)--Die Pharmakonzerne Regeneron und Sanofi SA dürfen ihr Medikament Libtay in den USA...
► Artikel lesen
MoRegeneron and Sanofi get FDA approval for Libtayo in non-small cell lung cancer11
SaCoronavirus-hit Czechs order Regeneron antibody drug ahead of EU registration39
17.02.Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE41
12.02.Roche's Faricimab On Par With Rival Regeneron's Aflibercept In Four Late-Stage Studies In Vision Loss Disorder41
12.02.Regeneron, Sanofi score again in long-running PCSK9 patent fight with Amgen55
12.02.Regeneron's therapy for rare heart disorder gets approved by FDA31
12.02.Regeneron, Sanofi's Libtayo shows extended overall survival in lung cancer study23
12.02.Amgen loses appeal in patent suit against Sanofi/Regeneron's Praluent. It's a bummer for Bristol Myers Squibb and Merck, too50
12.02.FDA approves Regeneron drug for rare, inherited form of high cholesterol16
11.02.US Federal Court Upholds Appeal In Favor Of Regeneron, Sanofi On Praluent467WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) Thursday announced that the United States Court of Appeals for the Federal Circuit upheld the decision by the U.S. District Court...
► Artikel lesen
11.02.Regeneron antibody earns nod for rare cholesterol disorder - but it ain't cheap11
11.02.FDA approves Regeneron's Evkeeza to treat ultra-rare inherited form of high cholesterol6
11.02.The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts16
11.02.BPTH On Steady Path, CGIX On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod558FOSTER CITY (dpa-AFX) - Today's Daily Dose brings you news about Bio-Path's patented DNAbilize platform technology, Cancer Genetics' stock offering, Galapagos/Gilead scrapping Ziritaxestat...
► Artikel lesen
10.02.Regeneron: Strong COVID Cocktail To Dope Normal Growth35
Seite:  Weiter >>
536 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
98,10,30